Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone
ESMO Virtual Congress 2020
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer. Long-term follow-up is ongoing (Abstract LBA12).
The ASCO Post Staff
Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses results of the nextMONARCH study, which indicated that combining abemaciclib with tamoxifen improved overall survival. Dr. Hamilton also details adverse events in different arms of the study (Abstract 273O).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may have a place in treating patients with metastatic renal cell carcinoma (Abstract 696O_PR).
The ASCO Post Staff
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the head and neck, in which the immune checkpoint inhibitor avelumab was combined with chemoradiotherapy followed by avelumab maintenance. Although the study results were negative, Dr. Cohen suggests other regimens that may prove to be effective (Abstract 910O).
The ASCO Post Staff
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with ipilimumab plus nivolumab (Abstract LBA45).
The ASCO Post Staff
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).
